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1. Introduction  
There are new drugs in medicine represent a revolution in therapeutics in the current era. 
These drugs are produced by different molecular biological techniques. Anti-tumor 
necrosis factor- α (anti-TNF-α) agents are important new class of the biological therapy of 
disease modifying antirheumatic drugs (DMARD). They target specific proteins of tumor 
necrosis factor- α (TNF-α) in the immune systems known to increase the inflammatory 
processes. Anti-TNF–α agents are increasingly used for a rapidly expanding number of 
rheumatic autoimmune diseases including rheumatoid arthritis (RA), ankylosing 
spondylitis (AS), crohn’s disease (CD), ulcerative colitis (UC), psoriasis, and psoriatic 
arthritis (PsA). They can increase odds of remission in both randomized controlled trials 
and clinical practice in early and established rheumatoid arthritis. They can withhold the 
radiological progression of certain diseases like RA. They can produce a dramatic 
normalization of acute phase reactants. Due to prolonged follow up periods, side effects 
profile for these agents is growing. This is in addition to their ability to neutralize specific 
immune pathways resulting in many adverse events.  Autoimmune syndromes with 
cutaneous and systemic manifestations including systemic lupus erythematosus may 
occur in patients receiving anti-TNF-α therapies (Ramos-Casals, Brito-Zeron et al. 2007). 
These agents represent a challenge for the practicing clinician with a range of judgments 
for optimal use and management of adverse events. In this chapter an overview of TNF-α 
will be demonstrated including its wide use in clinical practice. A more focus on anti-
TNF-α agents side effects profile will be presented particularly anti-TNF-α induced lupus 
erythematosus (ATIL). The chapter will address the various aspects related to ATIL 
including clinical manifestations, autoantibodies profile, management, prognosis and 
preventive strategies. 
2. Tumor necrosis factor-α (TNF-α)  
TNF and TNF receptors are members of a family of molecules (including Fas-ligand/fas, 
CD40 ligand/CD40) possessing crucial regulatory functions that include activation and 
apoptosis. TNF-α is an attractive therapeutic target owing to its abundant expression in 
the rheumatoid joint and plethora of proinflammatory effects that include regulation of 
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other proinflammatory mediators. TNF-α is a cytokine produced primarily by monocytes 
and macrophages but may also be produced by other cell types (e.g., B cells, T cells, mast 
cells, fibroblasts). TNF-α may further contribute to the pathogenesis of RA by induction of 
proinflammatory cytokines such as interleukin (IL)-1 and IL-6, enhancement of leukocyte 
migration by increasing endothelial layer permeability and expression of adhesion 
molecules by endothelial cells and leukocytes, activation of neutrophils and eosinophils, 
induction of the synthesis of acute-phase reactants, and the induction of tissue-degrading 
enzymes (matrix metalloproteinase enzymes) produced by synoviocytes and/or 
chondrocytes (Cush, Kavanaugh et al. 2011). It is expected then to have numerous 
biological effects in vivo with agents that inhibit the production or function of this 
cytokine.   
3. Anti-tumor necrosis factor-α (TNF-α) agents 
There are two strategies for inhibition of  TNF-α which can be achieved either with 
monoclonal antibody such as infliximab (Remicade), adalimumab (Humira), certolizumab 
pegol (Cimzia), and golimumab (Simponi), or with a circulating receptor fusion protein such 
as etanercept (Enbrel) (Fig 1).  
 
 
Fig. 1. Structure of anti- TNF-α agents.  
3.1 Infliximab (Remicade)   
Infliximab (Remicade) is a human/mouse chimeric monoclonal antibody against TNF-α and 
it was the first anti-TNF-α agent used to treat inflammatory disease. It was initially 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's 
disease in August 1998. Later on, it was approved by the FDA for the treatment of ulcerative 
colitis.  Infliximab works by blocking the action of TNF-α by preventing it from binding to 
its receptor in the cell and neutralizing its action. However, the powerful action of 
infliximab that it causes programmed cell death of TNF-α expressing activated T 
lymphocytes, a cell type mediating inflammation, which explains its efficacy in Crohn's 
disease.(Van den Brande, Braat et al. 2003). This is in contrast to another TNF-α neutralizing 
medication, etanercept, which is worse than a placebo in Crohn's disease.(Van Den Brande, 
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Peppelenbosch et al. 2002) Infliximab is administered as an intravenous infusion, on a 2-4 
weekly initially and then on a 6-8 weekly basis. 
3.2 Etanercept (Enbrel) 
Etanercept (Enbrel) is a p75 TNF--α receptor fusion protein produced through expression of 
recombinant DNA and conjugated to the Fc region of human immunoglobulin G (IgG1) 
which inhibits the binding of TNF to its cell surface receptor. Etanercept was developed by 
researchers at Immunex, and was released for commercial use in late 1998, soon after the 
release of infliximab.  There are two types of TNF receptors: those found embedded in white 
blood cells that respond to TNF by releasing other cytokines, and soluble TNF receptors 
which are used to deactivate TNF and blunt the immune response. Etanercept mimics the 
inhibitory effects of naturally occurring soluble TNF receptors, the difference being that 
etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly 
extended half-life in the bloodstream, and therefore a more profound and long-lasting 
biologic effect than a naturally occurring soluble TNF receptor. (Madhusudan, 
Muthuramalingam et al. 2005) The FDA has licensed etanercept for moderate to severe 
rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic 
arthritis, ankylosing spondylitis, and moderate to severe plaque psoriasis. Etanercept is 
administered as a subcutaneous injection with a dose of 25 mg twice weekly or 50 mg once 
weekly. 
3.3 Adalimumab (Humira) 
Adalimumab (Humira), the third approved TNF-α inhibitor after infliximab and etanercept, 
is a human anti-TNF-α monoclonal antibody. It binds to TNF-α preventing the activation of  
TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, 
while infliximab is a mouse/human chimeric antibody. In 2008, adalimumab has been 
approved by the FDA for the treatment of rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis, and crohn's disease. It is administered subcutaneously bi-weekly as 
preloaded 0.8 mL syringes or preloaded pen devices.  
3.4 Other anti- TNF-α agents 
Other two monoclonal antibodies targeting TNF-α are golimumab (Simponi), and 
certolizumab pegol (Cimzia); which is a Fab fragment of human anti-TNF-α antibody 
attached to a polyethylene glycol (PEG) moiety. In 2008, the FDA approved Cimzia for use 
in the treatment of crohn's disease in people who did not respond sufficiently or adequately 
to standard therapy. Large, randomized, double-blind trials in patients with rheumatoid 
arthritis have shown that golimumab in combination with methotrexate was more effective 
than methotrexate alone.(Oldfield and Plosker 2009). 
4. Indications 
The introduction of the TNF- α blocking therapies (anti-TNF) in 1998 marked the beginning 
of a new era in the treatment of chronic inflammatory human diseases, including RA, AS, 
psoriasis and PsA, and inflammatory bowel diseases. Infliximab, Etanercept, and 
adalimumab are the most common anti- TNF-α agents to be used with great response and 
disease control in the treated patients. The U.S FDA has approved the indications of anti 
TNF-α therapy (table 1). 
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Indication Etanercept Infliximab Adalimumab 
Rheumatoid 
arthritis (RA) 
Yes 1 Yes 1R Yes 1 
Early RA Yes Yes Yes 
Polyarticular 
juvenile arthritis 
Yes 2 -- -- 
Psoriatic arthritis Yes 3E Yes 3 Yes 3 
Ankylosing 
spondylitis 
Yes 4 Yes 4 Yes 4 
Psoriasis Yes 5 Yes -- 
Crohn disease -- Yes 6 Yes 6 
Ulcerative colitis -- Yes 7 -- 
1- Indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and 
improving physical function for patients with moderately to severely active rheumatoid arthritis. It can 
be initiated alone or in combination with methotrexate. 
       1R- Infliximab is approved for use in combination with methotrexate only. 
2- Indicated for reducing signs and symptoms of moderately to severely active polyarticular course 
juvenile rheumatoid arthritis patients who have had an inadequate response to one or more DMARDs. 
3- Indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis. 
       3E- Only etanercept is indicated to inhibit the progression of structural damage and improve 
physical function for patients with moderately to severely active psoriatic arthritis. It can be used in 
combination with methotrexate in patients who do not respond adequately to methotrexate alone. 
4- Indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. 
5-  Indicated for the treatment of adult patients (>18 years) with chronic moderate to severe plaque 
psoriasis who are candidates for systemic therapy or phototherapy. 
6- Indicated for reducing signs and symptoms and inducing or maintaining clinical remission in 
patients with moderately to severely active Crohn’s disease who have had an inadequate response to 
conventional therapy. Infliximab is also indicated for reducing the number of enterocutaneous and 
rectovaginal fistulas and maintaining fistula closure in fistulizing Crohn disease. 
7- Only infliximab is indicated for reducing signs and symptoms, achieving clinical remission and 
mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active 
ulcerative colitis who have had an inadequate response to conventional therapy. 
Table 1. U.S. Food and Drug administration-approved indications for anti-TNF-α therapy 
(Cush, Kavanaugh et al. 2011). 
4.1 Rheumatoid Arthritis (RA)  
RA is a chronic inflammatory autoimmune disease associated with debilitating and 
destructive polyarthritis and other systemic manifestations. DMARDs are used for 
treatment of patient with well-established RA and ongoing inflammation like methotrexate, 
sulfasalazine or hydroxychloroquine. If a patient had an inadequate response or intolerance 
to the usual treatment, biological therapy of anti-TNF-α can be used as monotherapy or in 
combination with other DMARDs. These recommendations have recently been modified 
because large controlled trials in early RA patients now allow their use as the initial 
DMARDs in RA. 
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4.2 Ankylosing Spondylitis (AS) 
AS is a chronic inflammatory disease, that affect young males. It is characterized by its 
association with HLA B27 antigen and spinal inflammation mainly in form of sacroilitis. 
Patients with active AS who did not respond to conventional therapies can be managed with 
anti -TNF-α therapy. 
4.3 Psoriasis and psoriatic arthritis 
Psoriatic arthritis is a potentially debilitating disease that may affect small and large 
peripheral joints, and the axial skeleton, seen in more than 10% of patients with plaque 
psoriasis. Arthritis may precede onset of skin disease. The conventional therapy of psoriatic 
arthritis includes non-steroidal anti-inflammatory drugs (NSAID), systemic and intra-
articular corticosteroids, and disease-modifying anti rheumatic drugs (DMARD) such as 
sulfasalazine or methotrexate. Recent trials in Psoriatic arthritis have shown excellent results 
with anti TNF-α therapy which have positive effects not only on joints, but also on the skin 
lesions.  
4.4 Inflammatory Bowel Diseases (IBD) 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the 
gastrointestinal tract. Although the primary etiological defect still remains unknown, 
genetic, environmental and microbial factors have been reported in activation of  
the mucosal immune response. TNF-α is one of the central cytokines in the underlying 
pathogenesis of mucosal inflammation which is responsible for the effectiveness of anti -
TNF-α therapy. Infliximab, adalimumab and certolizumab all seems to be effective in  
CD. Infliximab is the only anti-TNF agent currently approved for UC. Although 
etanercept is a TNF-α blocker, it is not approved and marketed for IBD. A randomized, 
controlled trial showed that etanercept was no better than placebo in IBD (Sandborn, 
Hanauer et al. 2001). Both etanercept and infliximab neutralized TNF-α, but only 
infliximab bounds to T lymphocytes and induces apoptosis of these cells (Van den 
Brande, Braat et al. 2003). 
4.5 Relative contraindications 
Due to the accumulative experience developing from the worldwide use of these drugs, 
certain conditions considered relative contraindications for the use of anti-TNF-α agents. 
Most of these conditions were obtained mainly from observations in randomized controlled 
trials and post-marketing phase IV trials. These conditions include systemic lupus 
erythematosus, lupus overlap syndrome, a history of demyelinating disorder (multiple 
sclerosis, optic neuritis), untreated active or latent tuberculosis, congestive heart failure, and 
pregnancy. The use of a TNF-α inhibitor in these conditions is currently experimental in 
terms of risks and benefits.   
5. Side effects  
Short- and long-term therapy with anti-TNF-α agents is well tolerated; however, the 
increased risk of infrequent but serious complications warrant sustained vigilance on the 
part of physicians and patients alike. 
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5.1 Injection site reaction 
Administration of anti -TNF-α either by intravenous infusion or subcutaneous injection may 
result in site reactions including development of redness, swelling, itching or even skin rash. 
Some patients report an allergic response to infliximab, possible reason may be due to its 
chimeric monoclonal antibody that has human part and mouse part.  
5.2 Infections 
TNF-α is a cytokine that plays a crucial role in the body's immune defense against bacterial 
infections. Infections are mainly consisting of upper respiratory tract infections, bronchitis 
and urinary tract infections. A systematic review of adverse effects of anti- TNF-α therapies 
as they were used in rheumatoid arthritis concluded that patients taking these agents are at 
2.0 time higher risk for serious infections. Serious infections that were observed, included 
pneumonia, sepsis and pyelonephritis (Leombruno, Einarson et al. 2009).                              
It has been documented well in the literature that treatment with anti-TNF-α agents is 
associated with increased rate of tuberculosis, in form of miliary, lymphatic, peritoneal, as 
well as pulmonary tuberculosis. Most of the cases of tuberculosis occurred within the first 
eight months after initiation of anti -TNF-α therapy.(Gomez-Reino, Carmona et al. 2003) As 
a result, it is recommended that patients should be screened with a TB skin test prior to 
starting these medications. If there is evidence of prior exposure with positive skin test, 
treatment for TB can be given in combination with the anti-TNF-α agents.                          
Other reported infections in patients on TNF-α inhibitors are fungal infections, such as 
pulmonary and disseminated histoplasmosis, coccidioidomycosis, and blastomycosis.  It is 
recommended that patients with active infections should not be started on anti -TNF-α 
agents until their infection resolve. Furthermore, these agents should be temporarily 
discontinued in those patients who develop an infection while on therapy.  
5.3 Malignancy 
The use of anti-TNF-α agents is accompanied by some worries about their long-term safety. 
Thus, it seems important to investigate whether blocking the action of this TNF-α cytokine 
might lead to an increased risk of malignancy. The particular worry concerns of 
lymphoproliferative malignancies, because these malignancies occur at an increased rate in 
immunosuppressed patients.  There are concomitant risk factors that may predispose to 
lymphoma in patients with RA who are using anti-TNF-α therapy. Patients with RA per se 
have an increased risk for developing lymphoma(Van den Brande, Braat et al. 2003). 
Patients specifically treated with anti -TNF-α agents are likely to have more severe disease 
regarding both disease duration and disease severity, which may increase the risk of 
malignant transformation. The accompanying use of medication, especially 
cyclophosphamide and azathioprine may increase the risk of developing malignancy (Van 
den Brande, Braat et al. 2003). In one study, it has been observed that there is an increased 
risk of lymphoproliferative malignancies in patients with RA who were treated with high-
dose azathioprine compared with non– azathioprine-treated RA controls (Silman, Petrie et 
al. 1988). In another study, an increased risk of bladder and skin cancer was observed in 
patients with RA who were treated with cyclophosphamide (Radis, Kahl et al. 1995). Most of 
the reported cases of lymphoma in patients with RA who were treated with methotrexate 
are related to Epstein-Barr virus (EBV) (Georgescu and Paget 1999). Methotrexate exposure 
is almost a universal practice in anti -TNF-α treated patients and could be an important 
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confounder of the subsequent risk for lymphoproliferative malignancies. In response to this 
risk of lymphoma, the US Food and Drug Administration (FDA) convened a meeting in 
March 2003 to review the safety data on TNF-α antagonists, focusing on the risk of 
malignancy in general and lymphoproliferative malignancies in particular(Kovacs, 
Vassilopoulos et al. 1996; Cush JJ 2003). Six lymphomas were found among 6303 RA patients 
treated with TNF-α inhibitors in controlled clinical trials, but none were observed in 
placebo-treated patients. A total of 23 lymphomas were observed (9 etanercept, 4 infliximab, 
10 adalimumab) during drug treatment, with an increased standardized incidence ratio 
(SIR, relative risk) of 3.47, 6.35, and 5.42, respectively (Cush JJ 2003). However, the 95% 
confidence intervals for these SIRs were particularly wide and overlapping, thus not 
permitting any separation of lymphoma risk due to drug or active RA alone. Rates of solid 
tumors were not increased when anti-TNF-α agents associated malignancies were compared 
with population expectations at an FDA meeting in 2003. Similarly, in registry studies, no 
overall increase in risk has been reported in RA patients whether or not exposed to TNF 
inhibitors (Cush JJ 2003). For all this evidence, there is no clear answer regarding the risk of 
developing lymphoma in patients with RA and on anti -TNF-α therapy, either if it is related 
to anti-TNF-α therapy or to RA itself and other confounding factors. 
5.4 Autoimmune diseases 
Anti-TNF-α agents are widely being used for a large number of patients with different 
rheumatic and systemic autoimmune diseases. As a result of this use, these agents have 
been associated with an increasing incidence of autoimmune diseases as adverse effects, 
principally vasculitis, lupus like syndrome, antiphospholipid-like features, and interstitial 
lung disease. Other autoimmune diseases have been described, such as sarcoidosis, 
autoimmune hepatitis, uveitis, and thyroiditis (Ramos-Casals, Brito-Zeron et al. 2008). The 
clinical characteristics, outcome and pattern of autoimmune diseases following TNF-α 
targeted therapies have been analyzed through a baseline Medline search of articles 
published between January 1990 and May 2008. A total of 379 cases have been reported with 
drug induced autoimmune diseases (table 2) (Ramos-Casals, Brito-Zeron et al. 2008). 
The reported cases of vasculitis have been classified into cutaneous vasculitis and visceral 
vasculitis (table 3) (Ramos-Casals, Brito-Zeron et al. 2008). Most of these cases of vasculitis 
overwhelmingly presented as cutaneous lesions, in form of purpura, ulcerative lesions, 
nodules or digital vasculitis. Regarding the biopsy, 75% of specimens were leukocytoclastic 
vasculitis, 15% necrotizing vasculitis, 5% lymphocytic vasculitis, and 2% urticarial 
vasculitis(Ramos-Casals, Brito-Zeron et al. 2008). Other patients may develop visceral 
vasculitis including peripheral nerve, renal, lung, and CNS involvements. Peripheral 
neuropathy may present in a form of axonal peripheral neuropathy, mononeuropathy 
multiplex, multifocal motor neuropathy with conduction block, or chronic inflammatory 
demyelinating polyradiculoneuropathy (Ramos-Casals, Brito-Zeron et al. 2008). Patients on 
anti -TNF-α   agents may develop glomerulonephritis (GN) with a biopsy of pauci-immune 
GN, crescenting necrotizing GN or IgA GN (Ramos-Casals, Brito-Zeron et al. 2008). 
Pulmonary involvement has been described in association with patients who are having 
perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) focal segmental necrotizing GN 
and crescentic GN. Rare cases have been reported with CNS involvement presented as 
central retinal artery occlusion, confusion of unclear origin and seizure(Ramos-Casals, Brito-
Zeron et al. 2008). Systemic vaculitis has been reported in a form of temporal arteritis, 
Henoch-Schonlein purpura, and polyarteritis nodosa (Ramos-Casals, Brito-Zeron et al. 2008).  
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Interstitial lung disease (ILD) has been developed after starting anti -TNF-α therapy in a form 
of interstitial pneumonitis, pulmonary hemorrhage and bronchiolitis obliterans organizing 
pneumonia. The specific feature of the ILD associated with anti-TNF-α therapy is the poor 
prognosis in spite of cessation of these agents. Therefore initiation of corticosteroids and 






















a) Systemic autoimmune diseases      
  DIL 140 49.51 ± 1.68 77 72, 7, 11 37, 33, 25, 6 
  Vasculitis 139 51.55 ± 2.68 79 92, 7, 8 43, 42, 7, 7 
  APS/APS-like disease 42 50.00 ± 3.79 70 26, 11, 26 45, 41, 5, 9 
  Sarcoidosis 38 49.41 ± 2.05 65 60, 37, 0 26, 61, 10, 3 
b) Organ-specific autoimmune diseases      
  Optical neuritisa 123 43.47 ± 3.29 63 37, 17, 25 43, 49, 7, 1 
  Interstitial lung disease 118 62.79 ± 1.98 77 77, 6, 4 43, 47, 3, 7 
  Inflammatory ocular disease 87 45.96 ± 2.16 81 41, 48, 0 18, 79, 2, 0 
  MS/MS-likea 55 42.83 ± 1.99 70 59, 17, 12 20, 51, 27, 2 
  Peripheral neuropathiesb 44 52.47 ± 2.16 66 61, 16, 16 74, 12, 14, 0 
  Autoimmune hepatitis 19 45.24 ± 2.83 76 32, 47, 21 79, 10, 10, 0 
DIL: drug-induced lupus; APS: antiphospholipid syndrome; MS: multiple sclerosis; RA: rheumatoid 
arthritis; Sp: spondyloarthropathies; IBD: inflammatory bowel disease; INF: infliximab; ETA: 
etanercept; ADA: adalimumab; SEM: standard error of the mean. 
a Eight patients had the two processes. 
b Excluding those appearing in patients with vasculitis. 
Table 2. Characteristic of main autoimmune diseases associated with biological agents 
(BIOGEAS Registry, last update July 15, 2009)(Ramos-Casals, Roberto Perez et al.).  
 
Clinical characteristics of Vasculitis Number of cases 





Not biopsied 37 
Peripheral neuropathy 18 
Glomerulonephritis 17 
Central nervous system 6 
Pulmonary involvement 3 
Systemic vasculitis 5 
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6. Anti-TNF-α Induced Lupus Erythematosus (ATIL) 
Drug induced lupus is a syndrome with symptoms, signs, and laboratory findings similar to 
idiopathic SLE. The diagnosis requires a temporal relationship between symptoms and 
therapy for at least four American Congress of Rheumatology criteria for SLE (Ramos-
Casals, Brito-Zeron et al. 2007). More than 80 drugs have been implicated in drug-induced 
lupus, with sulfadiazine being the first reported in 1945 (Vasoo 2006). The relationship 
between drugs and induced lupus was confirmed by the disappearance of symptoms with 
drugs withdrawal.  
Treatment with anti-TNF-α agents have been reported to be associated with drug-induced 
lupus erythematosus, most commonly with infliximab and etanercept, and rarely related to 
adalimumab (Haraoui and Keystone 2006; van Rijthoven, Bijlsma et al. 2006), as infliximab 
and etanercept have been used wider and for longer period than adalimumab. Lupus-like 
syndrome and ATIL were the most common in a registry of autoimmune diseases associated 
with anti-TNF-α agents (Ramos-Casals, Brito-Zeron et al. 2007). In this study, analysis of 92 
cases with ATIL revealed that all had clinical and immunological features suggestive of SLE, 
94% had positive autoantibodies, 89% had cutaneous features, 39% had musculoskeletal 
manifestations and general symptoms were presented in 29% (Ramos-Casals, Brito-Zeron et 
al. 2007).  
Majority of patients with ATIL were diagnosed with RA as it will be shown below. It can be 
argued that the development of ATIL was actually due to a change induced by anti-TNF-α 
agents from RA to SLE?  It is well recognized clinically that patients may evolve from one 
disease to another. It can be argued as well that those RA patients who developed ATIL 
were actually carrying the diagnosis of SLE but with a predominant presentation of 
polyarthritis and the use of anti-TNF-α agents had just triggered other lupus manifestations? 
This notion is supported, as it will be shown below by the fact that some patients with ATIL 
had positive ANA prior to initiation of Anti-TNF-α agents. All these arguments remain 
areas for ongoing research to help clinicians learn more about Anti-TNF-α agents and the 
actual pathogenesis of ATIL. It has to be noted that ATIL developed not only in RA patients 
but in patients with PsA, CD, and AS as well.  The abundance of case reports and case series 
support the notion that anti-TNF-α therapy can induce a lupus-like syndrome as a separate 
and well recognized clinical entity. Rigorous exclusion of SLE prior to initiation of Anti-
TNF-α agents is extremely important as a preventive action (see below).  
6.1 Role of TNF-α in the pathogenesis of SLE  
TNF-α is pleiotropism cytokine that has both immunoregulatory and proinflammatory 
effects, and its blockage has been proposed to be beneficial for the majority of patients with 
rheumatoid arthritis or inflammatory bowel disease. However, anti-TNF-α therapy has led 
in some cases to a significant incidence of drug-induced autoantibodies production and 
ATIL. TNF-α blocking could relieve the inflammation induced by TNF-α, at the same time 
the immunoregulatory and antiapoptotic effects of TNF-α could also be blocked which may 
lead to autoimmunity (Ramos-Casals, Brito-Zeron et al. 2007).  
6.1.1 Immunoregulatory effects and apoptosis of TNF-α in SLE 
In an experimental study, a heterozygous mice was generated which has reduced TNF-α 
production, by crossing NZB mice with TNF-α deficient mice. These mice developed 
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enhanced autoimmunity and severe renal disease similar to the classic mice model of SLE. 
Autoimmune responses were associated with an early spontaneous increase in serum levels 
of antinuclear antibodies (ANA) and hyperproliferating B cells which readily express anti-
double stranded DNA antibodies  (anti-ds DNA) antibodies specificities in response to 
polyclonal and T helper stimuli. These findings demonstrate a physiological role for TNF-α 
in suppressing the emergence of autoreactive lymphocytes in the NZB model and indicate 
that defective TNF-α function may be causative of the autoimmune and pathological 
phenomena in lupus. Loss of physiological TNF-α production in an autoimmunity prone 
background suffices to exacerbate antinuclear autoimmunity and the development of 
disease (Kontoyiannis and Kollias 2000).   
Apoptosis (programmed cell death (PCD)) plays an important role in the homeostasis of the 
immune response. Peripheral blood lymphocytes (PBLs) from SLE patients exhibit increased 
spontaneous and diminished activation induced apoptosis. Increased spontaneous 
apoptosis of PBLs has been linked to chronic lymphopenia and release of nuclear 
autoantigens in patients with SLE (Gergely, Grossman et al. 2002). The appearance of high 
numbers of autoreactive lymphocytes in the peripheral blood of patients with SLE might be 
a consequence of defective activation-induced cell death (Emlen, Niebur et al. 1994). It has 
been showed that permeabilitized lupus T cells displayed significantly lower amounts of 
TNF-α, a functional Fas/Fas-ligand path and adequate amounts of intracellular TNF-α were 
needed for the CD3-mediated T cell death. Prolonged survival of autoreactive T cells can 
lead to increased autoantibody production. Defective activation-induced apoptosis in lupus 
would worsen under TNF blockage (Kovacs, Vassilopoulos et al. 1996). 
The clinical reports about the levels of TNF-α in SLE patients’ were controversial. In most 
studies, TNF-α is found to be increased and appeared to be bioactive in the sera of patients 
with active SLE, and levels of TNF-α have been shown to correlate with SLE disease activity 
(Aringer, Feierl et al. 2002; Aringer and Smolen 2003). In another study, it has been found 
that SLE patients had elevated plasma levels of TNF-α with no correlation of disease activity 
(Zhu, Landolt-Marticorena et al. 2010).  Furthermore, in a third study, it has been 
demonstrated that TNF-α levels were higher in patients with inactive disease compared with 
patients with very active disease, suggesting that TNF-α could be a protective factor in SLE 
patients (Gomez, Correa et al. 2004).  
HLA-DR2 and DQwl positive subjects frequently exhibit low production of TNF-α whereas 
DR3 and DR4 positive subjects show high levels of TNF-α production. DR2 and DQwl 
positive SLE patients show low levels of TNF-α inducibility; this genotype is also associated 
with an increased incidence of lupus nephritis (LN). DR3 positive SLE patients, on the other 
hand, are not predisposed to nephritis, and these patients have high TNF-α production. DR4 
haplotype is associated with high TNF-α inducibility and is negatively correlated with LN. 
These data suggested that low TNF-α production may be involved in the genetic 
predisposition to LN, and may help explain the association between HLADR2/DQwl and 
susceptibility to LN (Jacob, Fronek et al. 1990).  
As TNF receptor1 (TNFR1)—TNFR associated death domain (TRADD)--Fas-associated 
death domain (FADD) system leading to apoptotic signaling, the down regulation of 
TRADD, FADD in patients with SLE may promote an anti-apoptotic effect. Defects in 
expression of these genes may increase the likelihood that lymphocytes avoid the normal 
processes used by the immune system to eliminate unwanted lymphocytes or to down-
regulate an immune response. If patients carry this autoimmune gene expression signature, 
signaling pathways essential for the maintenance of tolerance may not function properly. 
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This may permit lymphocytes to escape tolerance and adopt a pro survival agenda that 
increases the likelihood of autoimmune diseases (Rosen and Casciola-Rosen 2001), 
(Balomenos and Martinez 2000). 
The dysregulation of programmed cell death is suggested to be involved in the generation of 
autoantibodies. The low expression of TRADD, receptor-interacting protein 1 (RIP-1), and 
TNF receptor associated factor 2 (TRAF-2) might be one of the etiopathogeneses leading to 
redundant apoptotic death in SLE patients. It has been indicated that decreased expression 
of TRADD, RIP-1, and TRAF-2 and restrained pathogenesis for the loss of immune tolerance 
and redundant apoptotic cell death, leading to massive production of autoantibodies in SLE 
patients (Zhu, Yang et al. 2007).  
6.1.2 Inflammatory effects of TNF-α in the pathogenesis of SLE 
TNF-α is the most important proinflammatory cytokine and a harbinger of tissue 
destruction, and it is at the top of a pro-inflammatory “cascade” leading to tissue damage. In 
contrast to the complex role of TNF-α in apoptosis and in immune regulation, its powerful 
proinflammatory effects are unequivocal. It has been found that TNF-α is clearly expressed 
in glomeruli of LN patients, mainly by infiltrating macrophages but also by endothelial 
cells, glomerular visceral epithelium, and mesangial cells, with WHO class III and IV LN, 
while no TNF-α is detected in healthy kidney tissues. Most of the conducted studies have 
demonstrated that TNF-α is expressed in LN of all WHO classes and high TNF-α expression 
is associated with high histological disease activity. Also, it has been found that 
upregulation of renal expression of TNF-α in class III and class IV LN by 
immunohistochemical studies, and the upregulation of TNF-α was correlated with increased 
number of proliferating cell nuclear antigen (PCNA-)positive cells, CD68-positive cells and 
the activity index of renal pathologic changes (Aringer and Smolen 2004). 
6.2 Clinical trials of anti- TNF-α therapy in SLE 
SLE is a multifactorial autoimmune disease characterized by breakdown of self-tolerance, B 
cell hyperactivity, autoantibody production, aberrant formation of immune complexes, and 
inflammation of multiple organs. As TNF-α is a proinflammatory cytokine, participate in 
inflammatory tissue damage and in SLE pathogenesis, few clinical trials have been 
conducted regarding the use of anti TNF-α agents in patients with active SLE. 
In 2008, an open-label study was reported about the safety and efficacy of TNF-blockade in 
SLE. Seven patients with SLE were treated with infliximab at weeks 0, 2, 6, and 10 in 
combination with azathioprine or methotrexate. Autoantibodies to ds-DNA increased in 5 of 
7 patients. Histone levels were increased in 4 of 7 patients, and IgM anti-cardiolipin 
antibodies were also increased in 4 of 7 patients, peaking 4–10 weeks after the last infliximab 
infusion. This trial suggested that while anti-TNF-α agent was clinically effective, the 
majority of SLE patients treated with infliximab showed an increase in autoantibodies to 
nuclear antigens and phospholipids. These increases were transient and were not associated 
with disease flares (Aringer and Smolen 2008). A long-term follow up study was conducted 
of 13 patients about the adverse events and efficacy of TNF-α blockade with infliximab in 
SLE patients. It indicated that short-term therapy with four infusions of infliximab in 
combination with azathioprine was relatively safe and had remarkable long-term efficacy 
for LN and, potentially, also interstitial lung disease. Long-term therapy with infliximab, 
however, was associated with severe adverse events in two out of three SLE patients, which 
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may have been provoked by infliximab and/or by their long-standing refractory SLE and 
previous therapies(Aringer, Houssiau et al. 2009). 
6.3 Development of autoantibodies 
The induction of autoantibodies and anti-TNF-α therapy has been widely documented (De 
Bandt, Sibilia et al. 2005). Most of patients who were treated with anti-TNF-α agents 
developed antibodies that normally found almost exclusively in patients with SLE, however, 
these patients do not have any clinical features suggestive of SLE (Charles, Smeenk et al. 
2000). Therefore, discontinuation of these agents is not indicated but this evident do not 
exclude potential induction of clinical lupus signs or symptoms and patients need further 
close follow up and observation (Charles, Smeenk et al. 2000). TNF-α antagonists lead into 
an elevated titers of ANA with a homogeneous pattern in patients who already started 
treatment with positive serology of ANA. In addition, new onset of positive ANA may 
develop in previously negative ANA patients treated with TNF-α inhibitors (FDA 2008; Lin, 
Ziring et al. 2008). Development of new onset of anti-ds DNA antibodies, more specific 
antibodies of SLE, was reported during anti- TNF-α therapy which represents a strong 
evidence for diagnosis of induction of lupus-like syndrome following treatment with these 
agents. However, anti-ds DNA antibodies are found in 50-70% of patients with idiopathic 
SLE while their prevalence is from 9% to 33% in patients treated with anti- TNF-α (FDA 
2008; Lin, Ziring et al. 2008). It has been reported that patients on anti-TNF-α agents had 
serum antibodies to ds DNA of IgG, IgM, and IgA subtypes. In all reported patients, most 
common induced antibodies were solely of the IgM subtype. This finding is in marked 
contrast to the patients with idiopathic SLE, in whom although IgM antibodies to ds DNA 
are fairly common, it is extremely rare to find this response without accompanying IgG anti-
ds DNA antibodies (Charles, Smeenk et al. 2000). Anti-histone antibodies are detected in 
57% among patients with ATIL in one study (Costa, Said et al. 2008) and only in 17% in 
another study (De Bandt, Sibilia et al. 2005). It should be noted that anti-histone antibodies 
are not pathognomonic for drug-induced SLE and occur in more than 95% of cases, they are 
also found in 75% of cases with idiopathic SLE (Katz and Zandman-Goddard 2010). 
Hypocomplementemia is found in up to 59% of patients with ATIL while this finding is 
extremely rare in other drug-induced lupus (Costa, Said et al. 2008). The occurrence of 
anticardiolipin (ACL) antibodies were detected in anti-TNF-α treated patient. Up to 25% of 
patients on anti- TNF-α agents for RA developed IgG or IgM ACL, but thrombosis is 
observed in much fewer patients (about 4%) (Cambien, Bergmeier et al. 2003). It is also 
known that TNF-α has potent antithrombotic properties. It is therefore conceivable that the 
association of ACL antibodies and inhibition of TNF-α could lead to an increase risk of 
thrombosis. The presence of anti-Smith antibodies is almost exclusive of idiopathic SLE and 
rarely found in drug-induced SLE. Anti-nucleosome antibodies of the IgG subtype are 
considered to be a more sensitive marker for SLE than anti-dsDNA and anti-histone 
antibodies (Amoura, Koutouzov et al. 2000). Although there are number of patients who 
develop anti-nucleosome antibodies during treatment with anti- TNF-α agents, this number 
is not statistically significant. Positive ENAs also may develop in patients on these agents 
(Costa, Said et al. 2008). A comparison of different autoantibodies produced in ATIL 
reported in three different studies is presented in (table 4) (Williams, Gadola et al. 2009).  
It has been confirmed that the induction of ANA and anti-dsDNA antibodies occur in 
patients who started treatment with anti-TNF-α agents, and the presence of this serological 
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finding is unrelated to the genetic background or the underlying disease process. The 
development of only anti-dsDNA antibodies with absence of other lupus specific antibodies 
in the consequence of anti- TNF-α therapy is reassuring in terms of the safety of this 
treatment; however, long term observation is mandatory. 
Among laboratory findings, the hematological results that have been reported secondary to 
anti-TNF-α agents that are typical of idiopathic SLE which include leukopenia, 
thrombocytopenia, and lymphopenia (Costa, Said et al. 2008). 
 
Autoantibody Costa et al., 2008, 
(Britain), (n=33) 
Ramos et al., 2007, 
(Spain), (n=72) 
De Bandt et al., 
2005, (French), 
(n=12) 
ANA, n (%) 32/32 (100) 57 (79) 12 (100) 
dsDNA, n (%) 29/32 52 (72) 11 (92) 
Histone, n (%) 16/28 (57) Not reported 2 (17) 
aPL, n (%) Not reported 8 (11) 6 (50) 
ENAs, n (%) 10/19 (53) Anti-Sm 7 (10) 
Anti-Ro/La 9 (12) 
Anti-RNP 5 (7) 
5 (42) 
Table 4. Comparison of the developed antibodies in ATIL reported in three different studies 
(Williams, Gadola et al. 2009). ANA: antinuclear antibodies, dsDNA: double stranded DNA, 
aPL: antiphospholipid antibodies, ENAs: extractable nuclear antigens. 
6.4 Clinical manifestations of anti-TNF-induced SLE (ATIL) 
The true incidence of ATIL is difficult to establish due to the paucity of data and lack of 
double blind placebo-controlled prospective studies, difficulty to establish causality and 
lack of universal recognition of this relatively new entity (Katz and Zandman-Goddard). 
Post marketing studies on the three licensed anti-TNF-α agents have suggested an estimated 
incidence of ATIL of 0.19%–0.22% for infliximab, 0.18% for etanercept and 0.10% for 
adalimumab (De Bandt, Sibilia et al. 2005; Schiff, Burmester et al. 2006). However, the 
prevalence of ATIL in the main randomized controlled trials (RCTs) using anti-TNF agents 
is higher, with 14 (0.76%) cases in the 1842 patients included in 17 studies (Ramos-Casals, 
Roberto Perez et al.).  It has to be realized that this is an accumulative figure and it does not 
represent the exact prevalence. The mean duration of disease before initiation of anti-TNF-α 
therapy was 13.5 years in one cohort (range, 1-35 years)(Wetter and Davis 2009). Onset of 
symptoms ranges from less than one month to more than 4 years (Williams and Cohen). In 
another larger report, the mean latency time until the manifestations of ATIL was 41 weeks 
(Ramos-Casals, Brito-Zeron et al. 2007). There was, in this series, a 5:1 female : male ratio.  
The most common disease for which anti-TNF-α was used for was RA (Ramos-Casals, Brito-
Zeron et al. 2007; Costa, Said et al. 2008). Other diseases include but not limited to juvenile 
idiopathic arthritis, PsA, AS, CD. In one cohort, most patients who developed ATIL were 
having CD (Wetter and Davis 2009). The most common anti-TNF-α agent in use currently is 
infliximab as it is the first to be approved and introduced to clinical practice. Obviously, 
most of the cases of ATIL were due to infliximab use followed by etanercept and 
adalimumab respectively (Ramos-Casals, Brito-Zeron et al. 2007; Costa, Said et al. 2008). 
(Table 5) demonstrates the clinical characteristics of 92 patients with ATIL reported in the 
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literature up to December 2006 (Ramos-Casals, Brito-Zeron et al. 2007). (Table 6) 
demonstrates comparison of different features of ATIL reported in some studies (Williams, 
Gadola et al. 2009). 
 
Main Characteristic  No. (%) 
Underlying rheumatic disease (n=92)   
     Rheumatoid arthritis 
     Crohn disease 
     Ankylosing spondylitis  
     Psoriatic arthritis  






Anti-TNF agent (n=62)  
     Infliximab 
     Etanercept 




Demographic characteristics (n=62)  
     Female/male 
     Mean age at diagnosis of vasculitis 
(yr±SEM) 
     Length of anti-TNF treatment ± SEM 
(wk) 
52/10 
50.9 ± 2.3 
41.2 ± 5.7 
SLE criteria (n=72)  
     ANA  
     Anti-dsDNA 
     Cutaneous features  
     Arthritis 
     Cytopenia  
     Serositis  
     aPL 
     Anti-Sm antibodies  
     Nephropathy  
     Oral ulcers  












Number of SLE criteria fulfilled (n=72)  
≥ 4 (defined SLE) 
3 (lupus-like syndrome) 




Outcome (n=72)  
     Improvement  
     Time of improvement (mo ± SEM) 
      Rechallenge phenomenon 
71 
9.9 ± 1.4 
2/8 (33%) 
Table 5. Clinical characteristics of 92 patients with lupus related to TNF-targeted therapy 
(Ramos-Casals, Brito-Zeron et al. 2007). 
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criteria for lupus  
BSRBR data, 
(Britain), (n=41) 
Coasta et al., 
2008, (USA), 
(n=33) 
Ramos-Casal et al., 
(Spain), (n=72) 
De Bandt et al., 
2005, (France), 
(n=12) 
Malar rash. N (%) Not reported Not reported Not reported 5 (42) 
Discoid rash, n (%) 25 (61) 24 (73) 48 (67) 0 
Photosensitivity, n 
(%) 
4 (10) Not reported Not reported 5 (42) 
Oral ulcer, n (%) 5 (12) 1 (3) 3 (4) 0 
Arthritis, n (%) 3 (7) 17 (52) 22 (31) 6 (50) 
Serositis, n (%) 0 3 (18) 9 (12) 3 (25) 
Renal Disorder,  
n (%) 
0 3 (9) 5 (7) 0 
Neurological 
disorder, n (%) 
0 0 2 (3) 0 
Hematological 
disorder, n (%) 
1(2) 20 (61) Cytopenia-16 (22) 6 (50) 
Immunological 
disorder, n (%) 




antibodies, n (%) 
13 (32) 32 (97) 57 (79) 12 (100) 
Table 6. Features of patients with ATIL based on case reports and case series in some studies 
(Williams, Gadola et al. 2009).  
6.4.1 Development of cutaneous manifestations  
ATIL may present in variable forms of clinical features, either in form of isolated cutaneous 
manifestations or systemic manifestations. Most of the reported clinical features of anti-
TNF-α-induced SLE are in form of cutaneous lesions (tables 5 and 6). Most of these 
symptoms are similar to that symptoms present with idiopathic SLE. The cutaneous features 
of ATIL are most commonly malar rash, pruritic rash, photosensitive rash or purpura 
(Ramos-Casals, Brito-Zeron et al. 2008). Other cutaneous features are discoid rash, mucosal 
ulcers, and alopecia (Ramos-Casals, Brito-Zeron et al. 2008). The diagnosis of these 
cutaneous symptoms is based upon the clinical features in combination with concurrent use 
of an implicated drug. Therefore, many of the reported cases did not have skin lesions 
biopsied for diagnosis (Wetter and Davis 2009). When described, the pathological changes of 
this adverse effect are similar to those observed in patients with non-drug-associated 
idiopathic SLE (De Bandt, Sibilia et al. 2005; Costa, Said et al. 2008).  
6.4.2 Development of systemic manifestations 
Patients on anti- TNF-α therapy may develop systemic features of SLE that usually resolve 
after discontinuation of the offending drug. The associated general features include 
constitutional symptoms of fever, malaise, and weight loss which are considered as common 
symptoms of SLE after anti- TNF-α therapy and they often present in association with 
positive serology of autoantibodies. Other systemic symptom that reported is induction of 
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new onset of polyarthritis or progression to worsening symptoms of presented arthritis in 
form of joint tenderness, swelling, and effusion, some other patients develop arthralgia 
without evidence of arthritis (De Bandt, Sibilia et al. 2005). Arthritis was the first sign to 
develop in 71% in a cohort of patients in one center (Wetter and Davis 2009). It was also the 
most debilitating sign. Other rare and serious clinical characteristics may develop as side 
effects in patients on anti-TNF-α agents include serositis with pleurisy or pericarditis, 
pleural or pericardial effusions, deep venous thrombosis, life-threating pneumonitis, and 
neuritis (Costa, Said et al. 2008) (Table 7). Two cases of biopsy-confirmed proliferative lupus 
nephritis were described in patients treated with etanercept for juvenile RA (Mor, Bingham 
et al. 2005; Stokes, Foster et al. 2005). Renal biopsies revealed severe hypercellularity, 
endocapillary proliferation, wire loops and intraluminal deposits. Immunofluoresence 
shared positive staining for all immunoglobulin isotypes as well as C3 and Clq. Extensive 
electron-dense deposits were visualized by electron microscopy. Of note, focal proliferative 
lupus nephritis (Class III) was described with adalimumab (Stokes, Foster et al. 2005).  
 
Clinical manifestation Number of reported cases % of reported cases 
Rash 24/33 73 %  
Polysynovitis 17/33 52 % 
Fever 17/33 52 % 
Myalgias 8/33 24 % 
Pericardial/pleural effusion 3/33 9 % 
Nephritis 3/33 9 % 
Valvulitis 1/33 3 % 
Pneumonitis 1/33 3 % 
Deep venous thrombosis 1/33 3 % 
Oral ulcer 1/33 3 % 
Table 7. Clinical features of 33 reported cases with ATIL (Costa, Said et al. 2008). 
ATIL may present with unusual manifestation that is even uncommon feature of idiopathic 
SLE. This requires clinical suspension for ATIL in any patient presenting with unusual 
clinical findings. Invasive methods may be required to confirm the diagnosis. In a case that 
we reported (Almoallim 2011), adalimumab was initiated in a patient to control her 
symptoms of RA. She presented with prolonged morning stiffness and severe polyarthritis 
evident by swelling and tenderness in her metacarpophalangeal joints (MCPs), elbows, 
shoulders, knees and ankles. Serology for RF, anti-citrullinated protein antibodies (ACPA), 
and ANA (1:160) were all positive. While the patient was on adalimumab therapy, she 
showed significant improvement with complete remission of her disease. Within one year of 
this treatment, she developed diffuse muscle weakness mainly proximal rather than distal 
which made her unable to get up from the bed, climb stairs or even stand from sitting 
position. She had signs of active arthritis in two MCP joints in the right and bilateral wrist 
joints. She had mild hyperpigmented area around the mouth with no skin rashes elsewhere. 
She had a very high titer of ANA (1:1280) with emerging of a new onset of strongly positive 
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anti-ds DNA antibodies, her creatinine kinase was entirely normal. Electromyograghy 
(EMG) was suggestive of inflammatory myopathy. MRI deltoid and thigh showed mild 
edema involving the right triceps muscle with minimal enhancement in the post contrast 
sequence (Figure.2). Deltoid biopsy showed focal mild perivascular and endomysial 
lymphohistiocytic which revealed inflammatory myositis (Figure.3). Based on the clinical 
findings, the positive serology of ANA and anti-ds DNA, and the biopsy findings, the 
diagnosis of adalimumab induced lupus myositis was made. Given the profound muscle 
weakness that she had, she received 1 gm of pulse methylprednisolone intravenously daily 
for three days then she was maintained on 60 mg/day, in addition she received rituximab 
1000 mg intravenously, two doses in two weeks. This regimen was well tolerated and she 
recovered fully. Ten months later, she was asymptomatic with normal power, negative 
serology for anti-dsDNA antibodies and off treatment. In another case report, the patient 
developed severe myositis as a part of complex overlap syndrome following treatment with 
adalimumab, with positive serology for ANA and anti-dsDNA antibodies (Liozon, Ouattara 









Fig. 2. MRI right arm showed mild edema involving the right triceps muscle with minimal 








Fig. 3. Biopsy from right arm (triceps muscle) using Hematoxylin and Eosin stain, original 
magnification 400, which revealed inflammatory myositis (focal mild perivascular and 
endomysial lymphohistiocytic inflammation). 
6.5 Differences between ATIL and classic Drug Induced Lupus Erythematosus (DILE) 
These comparisons are observations based on the abundance of case reports in the literature. 
Skin rashes for example are thought to be more common in ATIL in comparison to DILE 
(Costa, Said et al. 2008). It is noticed that the classical cutaneous features of SLE is rare in 
DILE (Katz and Zandman-Goddard).  While myalgias is more common in DILE (Yung and 
Richardson 1994) in comparison to ATIL. The incidence of fever is similar in both diseases in 
one series (Costa, Said et al. 2008). (Table 8) represents the prevalence of clinical 
manifestations and laboratory features in ATIL, DILE and SLE as reported in three different 






realted lupus (%) 
Idiopathic SLE (%) 
ANA 79 >95 99 
Anti-dsDNA 72 <5 90 
Rash/cutaneous 
involvement 
67 <5 54-70 
Arthritis 31 20 83 
Fever/general symptoms 23 45 42 
Hypocomplementemia 17 <5 48 
Leukopenia 14 15 66 
Serositis 12 50 28 
Anticardiolipin antibodies 11 5-20 15 
Glomerulonephritis 7 <5 34 
Thrombocytopenia 6 <5 31 
Neuropsychiatric  3 <5 12 
Anti-histone antibodies Not reported >95 50-60 
Table 8. Prevalence of clinical manifestations and laboratory features in lupus related to 
anti-TNF agents compared with idiopathic SLE (Ramos-Casals, Brito-Zeron et al. 2007). 
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6.5 Diagnosis of Anti-TNF-α-induced lupus erythematosus 
Development of SLE in patients who is being treated with anti-TNF-α agents is well 
documented throughout the literature and the diagnosis of this side effect is crucial. The 
clinical presentation of ATIL can vary, and specific diagnostic criteria have not been 
established. However, in the most reported cases, the diagnosis was made on the basis of the 
development of one or more symptoms compatible with SLE, ongoing exposure to an anti--
TNF-α agent, no prior history of SLE, and resolution of symptoms when the offending drug 
is discontinued. The strict application of the American College of Rheumatology criteria for 
idiopathic SLE (ACR criteria) would probably exclude the diagnosis of ATIL in many 
patients receiving anti-TNF-α therapy. Therefore, for the purpose of early diagnosis; the 
following criteria can be considered (De Bandt, Sibilia et al. 2005): (1) a temporal relationship 
between symptoms and anti-TNF-α-therapy; (2) at least 1 serologic finding that compatible 
with ACR criteria eg, ANA, anti-dsDNA antibodies, and (3) at least 1 non serologic finding 
that compatible with ACR criteria eg, arthritis, serositis, hematologic disorder, malar rash. 
The musculoskeletal symptoms were taken into account only if they reappeared with other 
lupus symptoms in a patient in whom they had previously disappeared while receiving 
anti- TNF-α therapy as in the case reported above in section 6.4.2. Isolated positive results 
for ANAs or anti-dsDNA antibodies were not considered for diagnosis, given their high 
frequency in patients receiving this therapy (De Bandt, Sibilia et al. 2005). 
6.6 Treatment of Anti-TNF-α-induced Lupus Erythematosus (ATIL) 
The main approach regarding the treatment of ATIL is the withdrawal of offending drug. 
The time until symptoms resolution ranges from three weeks to six months (De Bandt, 
Sibilia et al. 2005; Wetter and Davis 2009). The level of autoantibodies have been either 
normalized or decreased in response to drug withdrawal (De Bandt, Sibilia et al. 2005; 
Wetter and Davis 2009). However, some investigators have suggested that TNF-α 
antagonists do not need to be discontinued if the patient has isolated induction of 
autoantibodies without any clinical manifestations of lupus (Ramos-Casals, Brito-Zeron et 
al. 2007; Kerbleski and Gottlieb 2009). It has to be realized that autoimmune diseases may 
coexist and there is always the possibility of latent idiopathic SLE triggered by anti-TNF-α 
agents. Strongly positive autoantibodies should raise the suspicion for ATIL. In addition to 
discontinuing of anti- TNF-α therapy, many patients required to be treated by the 
traditional therapy for idiopathic SLE to achieve full resolution of their lupus symptoms. 
The Spanish Study Group of Biological Agents in Autoimmune Diseases (BIOGEAS) 
classified all patients with autoimmune diseases secondary to the use of biologic agents into 
two groups, i.e. mild (with cutaneous, articular or general features) and severe (with 
pulmonary, renal or neurological involvement) disease (Ramos-Casals, Brito-Zeron et al. 
2007). For mild disease, it has been suggested to withdraw TNF-α antagonists and for severe 
disease, immediate cessation of the offending drug and addition of corticosteroids and other 
immunosuppressive agents. The British Society for Rheumatology’s (BSR) guidance for 
suspected ATIL recommends withdrawal of anti-TNF- α therapy, but does not specify 
additional treatment measures (Ledingham, Wilkinson et al. 2005).  It has been reported that 
lupus-like symptoms in patients receiving anti-TNF-α therapy disappeared in most of the 
cases after withdrawal of the anti- TNF-α therapy (Ramos-Casals, Brito-Zeron et al. 2007). 
Forty per cent of the patients also received corticosteroids, while 12% required additional 
immunosuppression with azathioprine, cyclophosphamide, leflunomide, methotrexate, 
mycophenolate or cyclophosphamide in one of the largest series of ATIL (Ramos-Casals, 
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Brito-Zeron et al. 2007). In a reported case of a patient who developed ATIL in a form of a 
pruritic photo-distributed skin rash after initiation of etanercept therapy, patient has been 
treated with hydroxychloroquine beside drug discontinuation and systemic 
corticosteroids(Williams and Cohen 2011). We reported case of a patient who developed 
lupus myositis after treatment with adalimumab for rheumatoid arthritis. She received 
pulse steroid therapy and two doses of rituximab. The treatment was well tolerated with 
complete recovery. The patient was then maintained on hydroxychloroquine and 
azothioprine. She remained asymptomatic for 10 months of follow up (Almoallim 2011).  An 
important question is whether patients with ATIL can safely receive an alternative anti–
TNF-α agent? There are limited evidences that support the safety of re-challenging with 
alternative anti-TNF-α agents.  Reports regarding this issue are scarce, but one author 
described 4 patients who were re-challenged with the same or different agents and had no 
recurrence of lupus symptoms (3 received etanercept and 1 received adalimumab)(Cush 
2004).   In another study, 4 of 5 patients tolerated an alternative TNF inhibitor (adalimumab 
for 3 patients, etanercept for 1) without recurrence of ATIL after discontinuation of 
infliximab (Wetter and Davis 2009). Nevertheless, these findings should be interpreted 
cautiously, given the small number of patients who were re-challenged.  In addition, some 
of these reports were conducted on patients with ATIL with mild disease and few clinical 
findings. The successful continued therapy with an alternative anti-TNF-α agent reported 
for one patient (Williams and Cohen), was actually manifested with only cutaneous 
findings. The clinical decision to continue an alternative anti-TNF-α agent in ATIL patients 
with severe and systemic involvement is really hard to make. Exposing patients to the risk 
of developing another serious complication from an offending drug, even if it were another 
drug in the same class is against the basic principles of safe practice.    
6.7 Prognosis of Anti-TNF-α -induced Lupus Erythematosus (ATIL) 
Most patients who developed ATIL had a good prognosis upon discontinuation of these 
agents. Normalization of the emerged autoantibodies and resolution of lupus symptoms 
occur when the offending drugs is stopped without recurrence. Some patients might need to 
be started on corticosteroids and immunosuppressive agents for full recovery as described 
above. However, patients who developed serious side effects in form of renal or 
neurological involvements may have residual effects (Ramos-Casals, Brito-Zeron et al. 2007).   
6.8 Prevention of Anti-TNF-α-induced Lupus Erythematosus (ATIL) 
ATIL is a well documented entity. Physicians need to use these biological agents in caution 
with close follow up. It is not known whether ATIL and other autoimmune phenomena are 
a contributing factor for the high rate of long-term drug failure/discontinuation of anti-
TNF-α therapy(Papagoras, Voulgari et al.) Rigorous follow up and early recognition of any 
complication developing while patients receiving anti-TNF-α agents, are essential to assure 
patients safety on the long term. This should help clinicians to learn more about these agents 
and identify appropriate approaches in different clinical settings encountered. As the use of 
anti-TNF-α agents has become more widely spread, the incidence of ATIL will likely also 
increase. There are currently no recommendations for prevention of ATIL. It has been 
suggested that concurrent use of immunosuppressive agents may reduce the incidence of 
autoantibody formation and thereby reduce the incidence of ATIL (Eriksson, Engstrand et 
al. 2005). Indeed, methotrexate can exert a suppressive effect on the production of 
autoantibodies in patients with isolated cutaneous lupus (Boehm, Boehm et al. 1998). 
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Although direct comparison between studies is difficult, as the majority of patients on anti-
TNF will also be taking MTX, data from clinical trials of infliximab in patients with RA 
suggest that concurrent therapy with DMARDs is not protective (Charles, Smeenk et al. 
2000; Eriksson, Engstrand et al. 2005). It has to be noted also that some RA patients had 
lupus features before the initiation of anti-TNF-α agents (Ramos-Casals, Brito-Zeron et al. 
2007). Use of anti-TNF-α agents may have triggered or unmasked the symptoms of SLE in 
some patients. For this reason, assuring the diagnosis of RA prior to initiation of anti-TNF-α 
therapy is an extremely important aspect in the prevention process. Presence of SLE is 
considered a contraindication to the use of anti-TNF-α therapy. Therefore, it is 
recommended to perform a thorough baseline immunological screening for any patient with 
definite polyarthritis to assure accurate diagnosis. It is recommended to perform a detailed 
immunological screening for any patient whom you are considering anti-TNF-α therapy for. 
Some recommendations have been suggested for each patient upon starting anti-TNF-α 
therapy which will help in the therapeutic approach for autoimmune diseases induced by 
these biological agents (Ramos-Casals, Brito-Zeron et al. 2007). First, perform baseline 
immunological analysis and chest X-ray before treatment. Second, maintain specific follow 
up centered on the possible development of cutaneous, articular, or pulmonary 
manifestations. Third, evaluate adverse effects related to anti-TNF-α accurately, discarding 
the existence of undiagnosed autoimmune diseases (mainly systemic vasculitis). Fourth, 
preexisting SLE, especially in the presence of sever organ involvement (renal, pulmonary, or 
neurogical), should be considered as a precautionary scenario for the use of anti-TNF-α 
therapy. Finally, anti-TNF-α agents should not be used in patients with preexisting 
interstitial lung disease (table 9). 
 
1. Perform baseline immunological analysis and chest X-ray before treatment. 
2. Maintain specific follow up centered on the possible development of cutaneous, 
articular, or pulmonary manifestations. 
3. Evaluate adverse effects related to anti-TNF-α accurately, discarding the existence of 
undiagnosed autoimmune diseases (mainly systemic vasculitis). 
4. Preexisting SLE, especially in the presence of sever organ involvement (renal, 
pulmonary, or neurogical), should be considered as a precautionary scenario for the 
use of anti-TNF-α therapy. 
5. Anti-TNF-α agents should not be used in patients with preexisting interstitial lung 
disease.   
Table 9. Some recommendations for each patient upon starting anti-TNF-α therapy. 
Adopted with modifications from (Ramos-Casals, Brito-Zeron et al. 2007).   
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